Search

Your search keyword '"Wöckel A"' showing total 2,492 results
Start Over Author "Wöckel A"
2,492 results on '"Wöckel A"'

102. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

103. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

104. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

105. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

107. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

Author

Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Würstlein, Rachel, additional

Published
2023
Full Text
View/download PDF

108. Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?

Author

Florian Ebner, Achim Wöckel, Lukas Schwentner, Maria Blettner, Wolfgang Janni, Rolf Kreienberg, and Manfred Wischnewsky

Subjects
Advanced breast cancer, Axillary dissection, Lymph nodes, Number of, Sentinel, Survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The decision making process for axillary dissection has changed in recent years for patients with early breast cancer and positive sentinel lymph nodes (LN). The question now arises, what is the optimal surgical treatment for patients with positive axillary LN (pN+). This article tries to answer the following questions:(1)Is there a survival benefit for breast cancer patients with 3 or more positive LN (pN3+) and with more than 10 removed LN?(2)Is there a survival benefit for high risk breast cancer patients (triple negative or Her2 + breast cancer) and with 3 or more positive LN (pN3+) with more than 10 removed LN?(3)In pN + patients is the prognostic value of the lymph node ratio (LNR) of pN+/pN removed impaired if 10 or less LN are removed? Methods A retrospective database analysis of the multi center cohort database BRENDA (breast cancer under evidence based guidelines) with data from 9625 patients from 17 breast centers was carried out. Guideline adherence was defined by the 2008 German National consensus guidelines. Results 2992 out of 9625 patients had histological confirmed positive lymph nodes. The most important factors for survival were intrinsic sub types, tumor size and guideline adherent chemo- and hormonal treatment (and age at diagnosis for overall survival (OAS)). Uni-and multivariable analyses for recurrence free survival (RFS) and OAS showed no significant survival benefit when removing more than 10 lymph nodes even for high-risk patients. The mean and median of LNR were significantly higher in the pN+ patients with ≤10 excised LN compared to patients with > 10 excised LN. LNR was in both, uni-and multivariable, analysis a highly significant prognostic factor for RFS and OAS in both subgroups of pN + patients with less respective more than 10 excised LN. Multivariable COX regression analysis was adjusted by age, tumor size, intrinsic sub types and guideline adherent adjuvant systemic therapy. Conclusion The removal of more than 10 LN did not result in a significant survival benefit even in high risk pN + breast cancer patients.

Published
2019
Full Text
View/download PDF

110. Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score

Author

Florian Ebner, Jessica Salmen, Davut Dayan, Matthias Kiesel, Regine Wolters, Wolfgang Janni, Achim Wöckel, and Manfred Wischnewsky

Subjects
Cancer Research, Oncology
Abstract

Purpose Although the incidence of distant relapse is decreasing, 20–30% of patients with early breast cancer die of metastasis. The aim of this study is to characterize patients with metastasis-free survival(MFS) less than 5 years, to analyze the most probable site of metastases according to the internally and externally validated BRENDA-score. The BRENDA-score is a combination of the biological subtype and clinical staging. Method 3832 patients with primary diagnosis of breast cancer and either distant metastatic recurrence within 5 years or MFS ≥ 5 years were assigned to this study. Patients were classified for metastatic recurrence according to the BRENDA-score. 1765 patients were in a validation set. Statistical methods were Kaplan–Meier curves, Cox regression analysis, Exhausted CHAID, likelihood-ratio tests and the Nearest Neighbor Estimation method. Results There was a significant(p Conclusion The evaluation showed that the BRENDA-Score is a robust predictive tool for breast cancer recurrence and site of metastases in the first five years after diagnosis. It outperforms intrinsic subtypes and the Nottingham prognostic score. The BRENDA-score could be a tool for a risk orientated and targeted follow up.

Published
2023
Full Text
View/download PDF

117. Update Mammakarzinom 2022 Teil 4 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Author

Bahriye Aktas, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A. Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Andreas D. Hartkopf, Achim Wöckel, Hans-Christian Kolberg, Elmar Stickeler, Nadia Harbeck, and Andreas Schneeweiss

Subjects
General Medicine
Abstract

ZusammenfassungFür die Behandlung von Patientinnen mit fortgeschrittenem HER2-negativem, hormonrezeptorpositivem Mammakarzinom sind in den letzten Jahren einige Substanzen in die Praxis eingeführt worden. Zusätzlich sind weitere Medikamente in der Entwicklung. Im letzten Jahr sind einige Studien veröffentlicht worden, die entweder einen Vorteil für das progressionsfreie Überleben oder aber auch für das Gesamtüberleben gezeigt haben. Diese Übersichtsarbeit fasst die neuesten Ergebnisse, welche auf aktuellen Kongressen oder in Fachzeitschriften veröffentlicht wurden, zusammen und ordnet sie in den klinischen Behandlungskontext ein. Insbesondere wird auf den Stellenwert einer Therapie mit CDK4/6 Inhibitoren, Trastuzumab-Deruxtecan, Sacituzumab-Govitecan und Capivasertib eingegangen. Für Trastuzumab-Deruxtecan wurde in der Destiny-Breast-04-Studie ein Gesamtüberlebensvorteil bei HER2-negativem Mammakarzinom mit einer niedrigen HER2-Expression (HER2-low expression) berichtet. Ebenso konnte ein Gesamtüberlebensvorteil in der FAKTION-Studie mit Capivasertib verzeichnet werden. Nach dem fehlenden Gesamtüberlebensvorteil für Palbociclib in der 1. Therapielinie stellt sich hier die Frage nach der klinischen Einordnung.

Published
2023
Full Text
View/download PDF

118. AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022

Author

Maggie Banys-Paluchowski, Marc Thill, Thorsten Kühn, Nina Ditsch, Jörg Heil, Achim Wöckel, Eva Fallenberg, Michael Friedrich, Sherko Kümmel, Volkmar Müller, Wolfgang Janni, Ute-Susann Albert, Ingo Bauerfeind, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Peter Fasching, Tanja Fehm, Oleg Gluz, Nadia Harbeck, Jens Huober, Christian Jackisch, Cornelia Kolberg-Liedtke, Hans H. Kreipe, David Krug, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Ulrike Nitz, Tjoung Won Park-Simon, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, H. Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Isabell Witzel, and Bernd Gerber

Subjects
General Medicine
Abstract

ZusammenfassungDie Empfehlungen der AGO-Kommission Mamma zur operativen Therapie des Mammakarzinoms wurden zuletzt im März 2022 aktualisiert (www.ago-online.de). Da die operative Therapie einen von mehreren Teilschritten bei der Behandlung des Mammakarzinoms darstellt, sind eine umfangreiche diagnostische und onkologische Expertise eines Brustoperateurs und eine gute interdisziplinäre Zusammenarbeit mit den diagnostischen Radiologen von großer Bedeutung. Die wichtigsten Änderungen betreffen die Lokalisationstechniken, die Resektionsränder, das axilläre Management im neoadjuvanten Setting und die Bewertung der Netze in der rekonstruktiven Chirurgie. Aufgrund von Metanaanalysen randomisierter Studien wurde der Empfehlungsgrad der intraoperativen Mammasonografie zur Lokalisation nicht palpabler Befunde auf „++“ erhöht. Somit wird die Technik als gleichwertig zur Drahtlokalisation angesehen, vorausgesetzt, es handelt sich um eine sonografisch gut darstellbare Läsion, der Operateur verfügt über umfangreiche Kenntnisse in der Mammasonografie und hat Zugang zu einem geeigneten Ultraschallgerät während der Operation. Beim invasiven Mammakarzinom wird das Erreichen von negativen Resektionsrändern („no tumor on ink“) angestrebt, unabhängig davon, ob eine extensive intraduktale Komponente vorliegt oder nicht. Onkoplastische Operationen können durch die Vielzahl der existierenden Techniken in ausgewählten Fällen auch eine Mastektomie ersetzen und sind im Vergleich zu einer regulären Segmentresektion hinsichtlich der onkologischen Sicherheit bei vergleichbaren Komplikationsraten gleichwertig. Patientinnen mit cN0-Status, die eine neoadjuvante Chemotherapie erhalten, wird eine Sentinel-Node-Exzision nach Abschluss der Chemotherapie empfohlen. Bei initial suspekten Lymphknoten wird die minimalinvasive Sicherung empfohlen. Nach der neoadjuvanten Chemotherapie stehen Patientinnen mit initial 1–3 suspekten Lymphknoten und gutem Ansprechen (ycN0) die „Targeted axillary Dissection“ und die Axilladissektion als gleichwertige Optionen zur Verfügung.

Published
2023
Full Text
View/download PDF

121. Update Mammakarzinom 2022 Teil 3 – Brustkrebs in frühen Krankheitsstadien

Author

Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A. Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Andreas Schneeweiss, Cornelia Kolberg-Liedtke, Andreas D. Hartkopf, Achim Wöckel, Hans-Christian Kolberg, Nadia Harbeck, and Elmar Stickeler

Subjects
General Medicine
Abstract

ZusammenfassungIn dieser Übersichtsarbeit werden neueste Entwicklungen in der Prävention von Brustkrebs und Behandlung von Patientinnen mit frühen Krankheitsstadien mit Mammakarzinom zusammengefasst. Die Ermittlung von individuellen Erkrankungsrisiken nach molekularen Subtypen wurde in einer großen epidemiologischen Studie untersucht. Im Bereich der Behandlung gibt es neue Daten zur Langzeitnachbeobachtung der Aphinity-Studie ebenso wie neue Daten zur neoadjuvanten Therapie von HER2-positiven Patientinnen mit Atezolizumab. Biomarker wie Residual Cancer Burden wurden im Zusammenhang mit einer Pembrolizumab-Therapie untersucht. Eine Untersuchung des Genomic-Grade-Indexes bei älteren Patientinnen reiht sich ein in die Gruppe von Studien, die versucht, durch moderne Multigentests Patientinnen zu identifizieren, bei denen eine Chemotherapie vermieden werden kann, weil diese eine exzellente Prognose haben. Diese und weitere Aspekte der neuesten Entwicklungen bei der Diagnostik und Therapie des Mammakarzinoms werden in dieser Übersichtsarbeit beschrieben.

Published
2022
Full Text
View/download PDF

122. Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Author

Volkmar Müller, Manfred Welslau, Diana Lüftner, Florian Schütz, Elmar Stickeler, Peter A. Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Tanja N. Fehm, Erik Belleville, Simon Bader, Katharina Seitz, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Andreas Schneeweiss, Nadia Harbeck, Rachel Würstlein, Andreas D. Hartkopf, Hans Christian Kolberg, and Achim Wöckel

Subjects
General Medicine
Abstract

ZusammenfassungFür Patientinnen mit einem fortgeschrittenen Mammakarzinom sind in den letzten Jahren mit den CDK4/6‑Inhibitoren, den Immuncheckpoint-Inhibitoren, den PARP-Inhibitoren, dem Alpelisib, Tucatinib und Trastuzumab-Deruxtecan sowie Sacituzumab-Govitecan einige Therapien neu etabliert worden, welche die Therapielandschaft von Patientinnen mit einem fortgeschrittenen Mammakarzinom deutlich verändert bzw. erweitert haben. Einige dieser Substanzen sind mittlerweile auch bei frühen Krankheitsstadien zugelassen bzw. eine Zulassung ist in naher Zukunft wahrscheinlich, sodass sich die Therapielandschaft abermals ändern wird. Die Einführung neuer Substanzen und das Verständnis der Progressions- und Effektivitätsmechanismen für diese Substanzen steht deswegen im Fokus der aktuellen wissenschaftlichen Bemühungen. In dieser Übersichtsarbeit werden die neuen Entwicklungen basierend auf aktuellen Publikationen und Kongressen zusammengefasst. Erkenntnisse zur Behandlung von Patientinnen mit einem HER2-positiven Mammakarzinom und Hirnmetastasen werden ebenso dargestellt wie eine Reihe von Studien, die sich mit Biomarkern bei Patientinnen mit HER2-negativem, hormonrezeptorpositivem Mammakarzinom beschäftigen. Insbesondere die Einführung der oralen, selektiven Östrogenrezeptor-Degradierer birgt neue Chancen, eine biomarkerbasierte Therapie zu etablieren. Die molekulare Diagnostik etabliert sich als diagnostischer Marker und Verlaufsparameter.

Published
2022
Full Text
View/download PDF

123. Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

Author

Michael Hudecek, Achim Wöckel, Jörg Wischhusen, Tanja Stüber, Razieh Monjezi, Lars Wallstabe, Johanna Kühnemundt, Sarah Louise Nietzer, Gudrun Dandekar, and Hermann Einsele

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background Immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both in the pre-clinical and clinical setting. A perceived barrier to the efficacy of CAR T-cell therapy in solid tumors is the hostile tumor microenvironment where immunosuppressive soluble factors like transforming growth factor (TGF)-β are thought to inhibit the cellular immune response. Here, we analyzed whether CAR T-cells specific for the receptor tyrosine kinase-like orphan receptor 1 (ROR1) antigen, that is frequently expressed in triple-negative breast cancer (TNBC), are susceptible to inhibition by TGF-β and evaluated TGF-β-receptor signaling blockade as a way of neutralizing the inhibitory effect of this cytokine.Methods CD8+ and CD4+ ROR1-CAR T-cells were prepared from healthy donors and their antitumor function analyzed using the TNBC cell line MDA-MB-231 in vitro and in a microphysiologic 3D tumor model. Analyses were performed in co-culture assays of ROR1-CAR T-cells and MDA-MB-231 cells with addition of exogenous TGF-β.Results The data show that exposure to TGF-β engages TGF-β-receptor signaling in CD8+ and CD4+ ROR1-CAR T-cells as evidenced by phosphorylation of small mothers against decapentaplegic homolog 2. In the presence of TGF-β, the cytolytic activity, cytokine production and proliferation of ROR1-CAR T-cells in co-culture with MDA-MB-231 TNBC cells were markedly impaired, and the viability of ROR1-CAR T-cells reduced. Blockade of TGF-β-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-β, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model. Combination treatment with SD-208 also led to increased viability and lower expression of PD-1 on ROR1-CAR T-cells at the end of the antitumor response.Conclusion We demonstrate the TGF-β suppresses the antitumor function of ROR1-CAR T-cells against TNBC in preclinical models. Our study supports the continued preclinical development and the clinical evaluation of combination treatments that shield CAR T-cells from TGF-β, as exemplified by the TGF-β-receptor kinase inhibitor SD-208 in this study.

Published
2020
Full Text
View/download PDF

124. Publikationsunterstützung für Mediziner – Bibliotheken als Servicepartner

Author

Wöckel, Claudia

Subjects
support services, scholarly communication, libraries, manuscript, Bibliography. Library science. Information resources, Medicine (General), R5-920
Abstract

This poster, presented at the 2019 AGMB conference, summarizes possible publication services for scientists. The focus is on support scientists in the medical field provided by libraries. The conference participants were encouraged to take part in a dot voting survey about possible services. The results will be summarized in this article.

Published
2019
Full Text
View/download PDF

125. Learn, share, act, bridge boarders… Der Blick über den Tellerrand

Author

Wöckel, Claudia

Subjects
eahil, publication services, workshop, creativity, report, Bibliography. Library science. Information resources, Medicine (General), R5-920
Abstract

The interactive format of the EAHIL workshop conference serves as a valuable platform for collegial advice. This short report describes several creative methods applied in the workshops. It is discussed which applications the methods have in library workspaces.

Published
2019
Full Text
View/download PDF

126. Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation

Author

Catharina Bartmann, Sudha R. Janaki Raman, Jessica Flöter, Almut Schulze, Katrin Bahlke, Jana Willingstorfer, Maria Strunz, Achim Wöckel, Rainer J. Klement, Michaela Kapp, Cholpon S. Djuzenova, Christoph Otto, and Ulrike Kämmerer

Subjects
Ketogenic diet, β-Hydroxybutyrate, Ketone bodies, Breast cancer, Seahorse, Metabolic profile, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Ketogenic diets (KDs) or short-term fasting are popular trends amongst supportive approaches for cancer patients. Beta-hydroxybutyrate (3-OHB) is the main physiological ketone body, whose concentration can reach plasma levels of 2–6 mM during KDs or fasting. The impact of 3-OHB on the biology of tumor cells described so far is contradictory. Therefore, we investigated the effect of a physiological concentration of 3 mM 3-OHB on metabolism, proliferation, and viability of breast cancer (BC) cells in vitro. Methods Seven different human BC cell lines (BT20, BT474, HBL100, MCF-7, MDA-MB 231, MDA-MB 468, and T47D) were cultured in medium with 5 mM glucose in the presence of 3 mM 3-OHB at mild hypoxia (5% oxygen) or normoxia (21% oxygen). Metabolic profiling was performed by quantification of the turnover of glucose, lactate, and 3-OHB and by Seahorse metabolic flux analysis. Expression of key enzymes of ketolysis as well as the main monocarboxylic acid transporter MCT2 and the glucose-transporter GLUT1 was analyzed by RT-qPCR and Western blotting. The effect of 3-OHB on short- and long-term cell proliferation as well as chemo- and radiosensitivity were also analyzed. Results 3-OHB significantly changed the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in BT20 cells resulting in a more oxidative energetic phenotype. MCF-7 and MDA-MB 468 cells had increased ECAR only in response to 3-OHB, while the other three cell types remained uninfluenced. All cells expressed MCT2 and GLUT1, thus being able to uptake the metabolites. The consumption of 3-OHB was not strongly linked to mRNA overexpression of key enzymes of ketolysis and did not correlate with lactate production and glucose consumption. Neither 3-OHB nor acetoacetate did interfere with proliferation. Further, 3-OHB incubation did not modify the response of the tested BC cell lines to chemotherapy or radiation. Conclusions We found that a physiological level of 3-OHB can change the energetic profile of some BC cell lines. However, 3-OHB failed to influence different biologic processes in these cells, e.g., cell proliferation and the response to common breast cancer chemotherapy and radiotherapy. Thus, we have no evidence that 3-OHB generally influences the biology of breast cancer cells in vitro.

Published
2018
Full Text
View/download PDF

130. Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Author

Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Würstlein, Rachel, additional, Krug, David, additional, Taran, Florin-Andrei, additional, and Lüftner, Diana, additional

Published
2023
Full Text
View/download PDF

131. Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Author

Lux, Michael P., additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Würstlein, Rachel, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Stickeler, Elmar, additional

Published
2023
Full Text
View/download PDF

134. Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease—the “Breast cancer care for patients with metastatic disease” (BRE-4-MED) registry

Author

Stangl, Stephanie, Haas, Kirsten, Eichner, Felizitas A., Grau, Anna, Selig, Udo, Ludwig, Timo, Fehm, Tanja, Stüber, Tanja, Rashid, Asarnusch, Kerscher, Alexander, Bargou, Ralf, Hermann, Silke, Arndt, Volker, Meyer, Martin, Wildner, Manfred, Faller, Hermann, Schrauder, Michael G., Weigel, Michael, Schlembach, Ulrich, Heuschmann, Peter U., and Wöckel, Achim

Published
2020
Full Text
View/download PDF

136. Patientenkompetenz zur Krankheitsbewältigung – Eine qualitative Analyse bei Frauen mit Brustkrebs und gynäkologischen Tumoren

Author

Karin Meng, Natascha Fahmer, Dirk Engehausen, Holger G. Hass, Monika Reuss-Borst, Kristin Duelli, Achim Wöckel, Peter U. Heuschmann, and Hermann Faller

Subjects
Psychiatry and Mental health, Clinical Psychology, Applied Psychology
Abstract

Zusammenfassung Ziel Die Studie exploriert Herausforderungen, persönliche Kompetenzen und hilfreiche Unterstützung bei der Krankheitsbewältigung von Patienteninnen mit Brustkrebs und gynäkologischen Tumoren und wie die Patientenkompetenz als Zusammenspiel dieser Faktoren gefördert werden kann. Methodik Teilstrukturierte Leitfadeninterviews wurden mit 19 Patientinnen im Akutsetting, 20 Rehabilitandinnen und 16 Teilnehmerinnen einer Selbsthilfegruppe geführt und mittels qualitativer Inhaltsanalyse ausgewertet. Ergebnisse Die thematisierten Herausforderungen sind in die Hauptkategorien – Diagnoseverarbeitung, Behandlungs-/Rezidivängste, Krankheitsverarbeitung und Adaptation, Sorgen um Angehörige, Reaktionen des sozialen Umfeldes, Sorgen um den Arbeitsplatz – zusammengefasst. Die benannten persönlichen Kompetenzen im Umgang mit diesen Herausforderungen sind den folgenden Hauptkategorien zugeordnet: kognitionsbezogenes Coping, handlungsbezogenes Coping, Selbstregulation Krankheitsverarbeitung, Unterstützung einholen und annehmen, selbstbestimmte Kommunikation der Erkrankung, hilfreiche Strategien identifizieren und anwenden, krankheitsbezogene Erfahrung, günstige Lebensumstände, Offenheit für Hilfsangebote. Hilfreiche emotionale, informationelle oder instrumentelle Unterstützung wird durch Angehörige, Freunde, Tiere, Arbeitskollegen/Arbeitgeber, Behandler, Rehabilitation, Mitpatientinnen/Betroffene, Selbsthilfe und Beratungseinrichtungen wahrgenommen. Diskussion Die Frauen beschreiben eine Vielzahl an persönlichen Kompetenzen, die einem bedürfnisorientierten, selbstgesteuerten Bewältigungsprozess entsprechen. Die Individualität und Komplexität des Zusammenspiels der Komponenten der Patientenkompetenz unterstreicht die Relevanz von patientenorientierter Versorgung. Empowerment und eine aktive Patientenrolle sind erforderlich, um bedürfnisbezogen Bewältigungsfertigkeiten zu fördern. Unterstützung durch Behandler oder das private Umfeld kann dabei Herausforderungen vermindern oder Kompetenzen und deren Anwendung fördern.

Published
2022
Full Text
View/download PDF

137. PERFORM: a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABC

Author

Michael Patrick Lux, Eva Diana Runkel, Esther Glastetter, Corinne Vannier, Johanna Buncke, Melanie Frank, Rupert Bartsch, Marc Thill, and Achim Wöckel

Subjects
Cancer Research, Oncology, General Medicine
Abstract

The prospective, non-interventional PERFORM study describes and analyzes the effectiveness of palbociclib in combination with endocrine therapy (aromatase inhibitor or fulvestrant) as first-line treatment for patients with locally advanced or metastatic HR+/HER2- breast cancer in the real-world setting in Germany and Austria. PERFORM will reflect current patient characteristics and routine treatment patterns including treatment sequences and time to subsequent (chemo)therapy. Besides, second-line treatment effectiveness and patient-relevant end points such as longitudinal patient-reported outcome measurements beyond disease progression will be analyzed. Accounting for the heterogenous real-world patient population, data on clinicopathologic subgroups underrepresented in clinical trials such as elderly or male will be analyzed. Taken together, PERFORM will close knowledge gaps from clinical trials in real world.Palbociclib in combination with endocrine therapy is the standard first-line treatment for patients with advanced HR+/HER2- breast cancer. Data from clinical trials have shown high response rates and good tolerability. To support these data and close potential knowledge gaps, we conduct the multicenter, observational PERFORM study to evaluate the effectiveness and patient-reported outcomes in patients with advanced HR+/HER2- breast cancer treated with endocrine-based palbociclib therapy in routine clinical practice in Germany.

Published
2022
Full Text
View/download PDF

139. Update Mammakarzinom 2022 Teil 1 – Brustkrebs in frühen Krankheitsstadien

Author

Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Elmar Stickeler, Peter A. Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Tanja N. Fehm, Erik Belleville, Simon Bader, Katharina Seitz, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Andreas Schneeweiss, Nadia Harbeck, Rachel Würstlein, Andreas D. Hartkopf, Achim Wöckel, Barbara Seliger, Chiara Massa, and Hans Christian Kolberg

Subjects
General Medicine
Abstract

ZusammenfassungDie Erkenntnisse über die Behandlung von Mammakarzinompatientinnen mit frühen Krankheitsstadien haben im letzten Jahr deutlich zugenommen. Abemaciclib, Olaparib und Pembrolizumab sind neue Medikamente mit einer guten Wirksamkeit bei den entsprechenden Patientinnengruppen. Jedoch sind einige Fragestellungen nach wie vor unbeantwortet. Insbesondere welchen Patientinnen unnötige Therapien erspart werden können, ist bei prämenopausalen Patientinnen mit einem hormonrezeptorpositiven Mammakarzinom weiterhin unklar. Die Frage, inwieweit eine Chemotherapie einen direkten zytotoxischen Effekt auf den Tumor hat oder eher dadurch wirkt, dass die Ovarfunktion durch die Chemotherapie reduziert wird, könnte wegweisend sein. Dieser Patientinnengruppe kann möglicherweise eine Chemotherapie erspart bleiben. Neue, bislang experimentelle Biomarker-Analysemethoden, wie die räumliche Analyse der Genexpression (spatial transcriptomics), halten nach und nach Einzug in die großen randomisierten Phase-III-Studien, wie die NeoTRIPStudie. Dies führt wiederum zum besseren Verständnis der prädiktiven Faktoren neuer Therapien, zum Beispiel der Immuntherapie. Diese Übersichtsarbeit fasst die wissenschaftlichen Neuerungen der aktuellen Kongresse wie dem San Antonio Breast Cancer Symposium 2021, aber auch von kürzlich veröffentlichten Publikationen zusammen.

Published
2022
Full Text
View/download PDF

141. Executive functions and borderline personality features in adolescents with major depressive disorder

Author

Albermann, Mona, Emery, Sophie, Baumgartner, Noemi, Strumberger, Michael, Erb, Suzanne, Wöckel, Lars, Müller-Knapp, Ulrich, Rhiner, Bruno, Contin-Waldvogel, Brigitte, Bachmann, Silke, Schmeck, Klaus, Berger, Gregor, Omega-3 Study Team, Häberling, Isabelle, and University of Zurich

Subjects
emotion regulation, executive function, 610 Medicine & health, major depressive disorder, adolescents, 10058 Department of Child and Adolescent Psychiatry, inhibition, borderline personality disorder
Published
2023
Full Text
View/download PDF

142. Sleep disturbance, but not depression severity, is associated with inflammation in children and adolescents

Author

Strumberger, Michael A, Häberling, Isabelle, Emery, Sophie, Albermann, Mona, Baumgartner, Noemi, Bucher, Naïma, Erb, Suzanne, Bachmann, Silke, Wöckel, Lars, Müller-Knapp, Ulrich, Contin-Waldvogel, Brigitte, Rhiner, Bruno, Walitza, Susanne, Berger, Gregor, Cajochen, Christian, Schmeck, Klaus, and University of Zurich

Subjects
BMI, reactive protein, inflammation, sleep, depression, 610 Medicine & health, adolescence, 10058 Department of Child and Adolescent Psychiatry
Published
2023
Full Text
View/download PDF

148. Differences in serum zinc levels in acutely ill and remitted adolescents and young adults with bulimia nervosa in comparison with healthy controls – a cross-sectional pilot study

Author

Zepf FD, Rao P, Runions K, Stewart RM, Moore JK, Wong JWY, Linden M, Sungurtekin I, Glass F, Gut L, Peetz D, Hintereder G, Schaab M, Poustka F, and Wöckel L

Subjects
Bulimia nervosa, zinc, serum concentrations, remission, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Florian D Zepf,1,2 Pradeep Rao,1,3 Kevin Runions,3,4 Richard M Stewart,1 Julia K Moore,1,5 Janice WY Wong,1,4 Maike Linden,1,2,6 Idil Sungurtekin,7 Franziska Glass,8 Linda Gut,8 Dirk Peetz,9,10 Gudrun Hintereder,11 Michael Schaab,12 Fritz Poustka,8 Lars Wöckel8,13 1Centre and Discipline of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Western Australia, 2Specialised Child and Adolescent Mental Health Services (CAMHS), Department of Health in Western Australia, 3Community Child and Adolescent Mental Health Services, Department of Health in Western Australia, 4Telethon Kids Institute, University of Western Australia, 5Paediatric Consultation-Liaison Program, Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia; 6Clinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, 7Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, 8Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University, Frankfurt am Main, 9Institute of Laboratory Medicine, HELIOS Klinikum Berlin-Buch, Berlin, 10Department of Clinical Chemistry and Laboratory Medicine, University Center of the Johannes Gutenberg University Mainz, Mainz, 11Department of Laboratory Medicine, Goethe University, Frankfurt am Main, 12Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany; 13Center of Child and Adolescent Psychiatry and Psychotherapy, Clienia Littenheid AG, Littenheid, Switzerland Background: Research has implicated that changes in zinc (Zn) metabolism may be associated with the biological underpinnings of eating disorders, in particular anorexia nervosa. However, to date research on the role of Zn in patients with bulimia nervosa (BN) is scarce.Objective: We aimed to explore serum Zn concentrations in young patients with BN, with a focus on the stage of the disorder, comparing acutely ill and recovered patients with BN with healthy controls.Methods: Serum Zn concentrations were obtained from healthy controls and from acutely ill and remitted young patients with BN. Mean duration of remission was 4.0±3.5 years.Results: Remitted patients showed elevated serum Zn concentrations when compared to controls (Cohen’s d=2.022), but concentrations were still in the normal range. Acutely ill patients also had higher serum Zn levels when compared to controls (all values still being within the reference range, Cohen’s d=0.882). There was no difference between acutely ill and remitted patients with BN in serum Zn concentrations. Of note, remitted patients had a significantly higher body weight when compared to the other two groups. Overall, there were no significant differences in dietary preferences with regard to Zn containing foods between the groups.Conclusion: The present study provides preliminary evidence that the underlying factors for changes in Zn serum concentrations in young patients with BN do not vary with regard to the stage of illness (acute versus remitted BN). Further prospective research is needed in order to disentangle the possible interplay between serum Zn status and bulimic eating behaviors. Keywords: bulimia nervosa, zinc, serum concentrations, remission, eating disorders

Published
2017

149. Update Mammakarzinom 2021 Teil 4 – Prävention und frühe Krankheitsstadien

Author

Christoph Thomssen, Tanja N. Fehm, Elmar Stickeler, Peter A. Fasching, Wolfgang Janni, Cornelia Kolberg-Liedtke, Hans-Christian Kolberg, Diana Lüftner, Volkmar Müller, Florian Schütz, Erik Belleville, Simon Bader, Michael Untch, Manfred Welslau, Marc Thill, Andreas D. Hartkopf, Hans Tesch, Nina Ditsch, Michael P. Lux, Achim Wöckel, Bahriye Aktas, Andreas Schneeweiss, and Rachel Würstlein

Subjects
General Medicine
Abstract

ZusammenfassungIm vergangenen Jahr wurden für viele Patientinnen mit Mammakarzinom in frühem Krankheitsstadium neue und effektive Optionen für eine weitere Verbesserung der Behandlungsergebnisse gezeigt. Für Patientinnen mit hormonrezeptorpositiver Erkrankung zeigte sich ein signifikanter Zusatzeffekt durch den Einsatz des CDK4/6-Inhibitors Abemaciclib zusätzlich zur endokrinen adjuvanten Therapie. Bei triple-negativer Erkrankung wurden Daten für 2 Therapieprinzipien gezeigt. Patientinnen mit fortgeschrittener Erkrankung (Stadium 2 und 3) profitieren von dem neoadjuvanten Einsatz des Immuncheckpoint-Inhibitors Pembrolizumab unabhängig von der PD‑L1-Expression in Kombination mit einer Standardchemotherapie. Bei BRCA1- oder BRCA2-Mutation wurde ein eindrucksvoller Benefit durch den Einsatz des PARP-Inhibitors Olaparib gezeigt, wenn die neoadjuvante Therapie nicht zur gewünschten Remission geführt hat. Weitere Daten betreffen translationale Fragestellungen beim HER2-positiven Mammakarzinom sowie neoadjuvante Therapieansätze mit dem oralen SERD Giredestrant und dem PARP-Inhibitor Talazoparib. In dieser Übersichtsarbeit werden die Ergebnisse der wichtigsten Studienergebnisse dieses Jahres vorgestellt und bewertet.

Published
2022
Full Text
View/download PDF

150. 213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe

Author

Oikonomidou, O., primary, Galve-Calvo, E., additional, Wöckel, A., additional, Parikh, R., additional, Hitchens, A., additional, Chen, C., additional, Gauthier, E., additional, Li, B., additional, Ansquer, V. Derrien, additional, Frugier, G., additional, Jimenez, M., additional, Davis, K., additional, and Broughton, E., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results